Related Experiment Video

Updated: Mar 28, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer

Jianlin Xu1, Tianqing Chu1, Bo Jin1

  • 1Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.

Clinical Lung Cancer
|January 5, 2016
PubMed
Abstract

Insights

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show improved survival in lung squamous cell carcinoma (SCC) patients with EGFR mutations. EGFR testing helps identify patients who benefit most from TKI therapy for SCC.

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Genetics

Background:

  • The effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in lung squamous cell carcinoma (SCC) is debated.
  • The utility of EGFR testing for guiding SCC treatment is unclear.

Purpose of the Study:

  • To evaluate the efficacy of EGFR TKIs in patients with stage IIIB or IV lung SCC.
  • To determine if EGFR mutation status influences TKI treatment outcomes.

Main Methods:

  • Retrospective analysis of lung SCC patients who underwent EGFR testing.
  • Comparison of overall survival (OS) and progression-free survival (PFS) between TKI-treated and non-TKI-treated groups, stratified by EGFR mutation status.

Main Results:

  • EGFR mutation-positive patients receiving TKIs had significantly improved OS compared to those without TKIs (18.04 vs 13.18 months, P = .015).
  • Patients with wild-type EGFR showed no OS improvement with TKIs (14.03 vs 13.63 months, P = .927).
  • Progression-free survival was significantly longer in EGFR mutation-positive patients compared to wild-type patients (3.94 vs 1.94 months, P = .004).

Conclusions:

  • EGFR TKIs represent a potential treatment option for lung SCC.
  • EGFR mutation testing is valuable for selecting SCC patients likely to respond to TKI therapy.
Keywords:
EGFRMutationNSCLCSCCTKI therapy

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
637
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K